Hydroxymethylglutaryl‐CoA Reductase Inhibitors in Older Persons with Acute Myocardial Infarction: Evidence for an Age–Statin Interaction
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To characterize the relationship between hydroxymethylglutaryl‐CoA reductase inhibitors (statins) and outcomes in older persons with acute myocardial infarction (AMI). DESIGN: Observational study. SETTING: Acute care hospitals in the United States from April 1998 to June 2001. PARTICIPANTS: Medicare patients aged 65 and older with a principal discharge diagnosis of AMI (N=65,020) who did and did not receive a discharge prescription for statins. MEASUREMENTS: The primary outcome of interest was all‐cause mortality at 3 years after discharge. RESULTS: Of 23,013 patients with AMI assessed, 5,513 (24.0%) were receiving a statin at discharge. Nearly 40% of eligible patients (n=8,452) were aged 80 and older, of whom 1,310 (15.5%) were receiving a statin at discharge. In a multivariable model taking into account demographic, clinical, physician and hospital characteristics, and propensity score, discharge statin therapy was associated with significantly lower 3‐year mortality (hazard ratio (HR)=0.89 (95% confidence interval (CI)=0.83–0.96)). In an analysis stratified by age, discharge statins were associated with lower mortality in patients younger than 80 (HR=0.84, 95% CI=0.76–0.92) but not in those aged 80 and older (HR=0.97, 95% CI=0.87–1.09). CONCLUSION: Statin therapy is associated with lower mortality in older patients with AMI younger than 80 but not in those aged 80 and older, as a group. This finding questions whether statin efficacy data in younger patients can be broadly applied to the very old and indicates the need for further study of this group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Lakatta, E. G., & Levy, D. (2003) · Circulation · doi:10.1161/01.cir.0000048892.83521.58 · Cited by 2,244
de Lemos, J. A., Blazing, M. A., Wiviott, S. D., Lewis, E. F., Fox, K. A. A., White, H. D., Rouleau, J.-L., Pedersen, T. R., Gardner, L. H., Mukherjee, R., et al. (2004) · JAMA · doi:10.1001/jama.292.11.1307 · Cited by 1,333
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Writing Committee Members:, Pasternak, R. C., Smith, S. C., Bairey-Merz, C. N., Grundy, S. M., Cleeman, J. I., & Lenfant, C. (2002) · Circulation · doi:10.1161/01.cir.0000032466.44170.44 · Cited by 1,088
Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions
Bellosta, S., Paoletti, R., & Corsini, A. (2004) · Circulation · doi:10.1161/01.cir.0000131519.15067.1f · Cited by 578 · cited 1×
“Treatment in people aged 80 and older therefore has more potential for adverse events than treatment in younger populations, in whom the most common adverse effects are asymptomatic elevations in hepatic transaminases and myopathy.(28) Drug toxicity is a particular concern in people aged 80 and older, the majority of…”
BackgroundThe safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk
Corsini, A. (2003) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1026132412074 · Cited by 82 · cited 1×
“Because all statins undergo metabolism by the cytochrome P450 isoenzyme system to varying degrees, the potential for drug interactions is increased, although side effects occurred in only 3% of patients concurrently taking medications that could potentially interact.(29) Given the potential side effects of therapy,(30…”
Background
Cited by
Armitage, J., Baigent, C., Barnes, E., Betteridge, D. J., Blackwell, L., Blazing, M., Bowman, L., Braunwald, E., Byington, R., Cannon, C., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31942-1 · Cited by 801
Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update
Mosca, L., Banka, C. L., Benjamin, E. J., Berra, K., Bushnell, C., Dolor, R. J., Ganiats, T. G., Gomes, A. S., Gornik, H. L., Gracia, C., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.020 · Cited by 757
Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update
Mosca, L., Banka, C. L., Benjamin, E. J., Berra, K., Bushnell, C., Dolor, R. J., Ganiats, T. G., Gomes, A. S., Gornik, H. L., Gracia, C., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.181546 · Cited by 579
Danaei, G., Tavakkoli, M., & Hernán, M. A. (2012) · American Journal of Epidemiology · doi:10.1093/aje/kwr301 · Cited by 264
Derhovanessian, E., Solana, R., Larbi, A., & Pawelec, G. (2008) · Immunity & Ageing · doi:10.1186/1742-4933-5-11 · Cited by 169
Metadata
- Authors
- Micale Foody, J., Rathore, S. S., Galusha, D., Masoudi, F. A., Havranek, E. P., Radford, M. J., & Krumholz, H. M.
- Venue
- Journal of the American Geriatrics Society
- Publisher
- Wiley
- Published
- 2006-03
- Volume
- 54
- Issue
- 3
- Pages
- 421-430
- ISSN
- 0002-8614 (ISSN-L)
- 1532-5415
- OpenAlex
- W1788350776
- Cited by
- 80
- References
- 10
- FWCI
- 7.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hydroxymethylglutaryl‐CoA Reductase Inhibitors in Older Persons with Acute Myocardial Infarction: Evidence for an Age–Statin Interaction. https://app.cochat.ai/papers/10.1111/j.1532-5415.2005.00635.x
- The paper
- Micale Foody, J., Rathore, S. S., Galusha, D., Masoudi, F. A., Havranek, E. P., Radford, M. J., & Krumholz, H. M. (2006). Hydroxymethylglutaryl‐CoA Reductase Inhibitors in Older Persons with Acute Myocardial Infarction: Evidence for an Age–Statin Interaction. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.2005.00635.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.